# There's a $300K/month app you've never heard of. The GLP-1 app gold rush nobody is talking about.
**作者**: Lucas Patiri
**日期**: 2026-04-21T13:10:58.000Z
**来源**: [https://x.com/lucaspatiri_/status/2046577435269898403](https://x.com/lucaspatiri_/status/2046577435269898403)
---
30 million people on weight loss drugs. Almost none of them use a dedicated app. Zero creator marketing in the category (atm). This is the biggest untapped vertical in mobile.
30 million people worldwide are currently on GLP-1 drugs. Ozempic, Wegovy, Mounjaro, Zepbound. One in eight American adults is taking one right now.
The GLP-1 drug market is worth over $50 billion and growing at 20%+ per year. By 2030 it will be the largest pharmaceutical category in history.
And yet almost nobody in the app growth world is paying attention to the software layer being built on top of it.
Theres a GLP-1 tracking app called Shotsy doing $300K/month in revenue. 40K downloads per month. Nearly 1 million total users. And its ranked #152 in Health & Fitness on the US App Store.
Youve probably never heard of it.
Heres why this matters: the GLP-1 app category is where fitness apps were in 2018. Early, growing fast, massive TAM, and almost zero sophistication in how these apps acquire and retain users.
Nobody in this space is running creator campaigns. Nobody is doing UGC at scale. The entire category is growing on organic word-of-mouth from Reddit forums and doctor referrals.
If you're an app founder looking for your next vertical, or a growth operator looking for an underserved market, this is it.
The numbers.
Lets start with the drug market because the app opportunity is a direct function of it.
· 30 million people currently on GLP-1s globally
· 1 in 8 US adults currently taking a GLP-1 drug
· 27% of global adults are eligible for GLP-1 treatment
· $50-80 billion drug market in 2026, growing 20%+ Compound Annual Growth Rate
· 55 million Americans projected on GLP-1s by 2035
Now the app side:
· Shotsy: $300K/month revenue, 40K downloads/month, ~1M total users
· MeAgain: 250K+ users, 4.81 stars, subscription model
· Pep: 11K+ downloads, growing fast
· PeptideCalc: 4.99 one-time purchase, 4.9 stars, niche but loyal
· Total category revenue: estimated $5-6M/year across all apps
That last number is the one that should jump out. $5-6M/year serving a market of 30 million users means less than 1% penetration. The top app in the space is making $3.6M/year in a $50B+ market.
For comparison: Cal AI hit $50M ARR serving a calorie tracking market that's a fraction of the size. The GLP-1 app opportunity is bigger and less competitive.
Why nobody is marketing these apps.
I looked at every major GLP-1 app and checked their growth channels. Here's what I found:
· Zero active UGC or creator campaigns on TikTok, Reels, or Shorts
· No visible influencer partnerships
· No paid social ad libraries on Meta or TikTok
· Growth is almost entirely organic: Reddit (r/Mounjaro, r/tirzepatidecompound), doctor referrals, and App Store search
This is exactly where fitness apps were 5 years ago. Before Cal AI spent $0 on ads and got 250M views. Before apps like Hevy and Lose It built creator networks. Before UGC became the default growth engine for health apps.
The GLP-1 app space hasnt had its UGC moment yet. When it does, the first mover will dominate.
Why creator content is perfect for this vertical.
GLP-1 content is already exploding on social. There are millions of organic posts about Ozempic, Mounjaro, weight loss journeys, side effects, meal planning on GLP-1s. The audience exists. The content demand exists. Nobody is funneling it to an app.
Here's why creator marketing works especially well here:
## 1. The before-after format is built into the product.
Weight loss is the most visual transformation category that exists. Every GLP-1 user has a before-after story. Creators showing their 3-month or 6-month transformation while crediting the app that helped them track it is the most natural ad format possible.
Cal AI understood this. Their best-performing content was always before-after. GLP-1 apps havent figured it out yet.
## 2. The audience is desperate for guidance and community.
Starting a GLP-1 is confusing and scary. Dosing schedules, reconstitution (for compounded), injection sites, side effects, protein requirements, hydration. People are overwhelmed.
A creator who says "heres the app I use to track everything" provides immediate value. Its not a pitch, its a lifeline. That conversion intent is stronger than almost any other vertical.
## 3. The stigma creates intimacy.
Theres still stigma around weight loss drugs. People don't always talk about it openly. But they DO engage with creator content from people who share their experience authentically.
Creators who are open about their GLP-1 journey build unusually deep trust with their audience. That trust transfers directly to the app they recommend. Conversion rates in stigmatized health verticals are typically 2-3x higher than general health content.
## 4. Medical content has higher retention.
GLP-1 tracking is a daily habit tied to a medical routine. Retention curves for medication tracking apps are significantly flatter than general fitness apps.
Higher retention = higher LTV = more budget available for acquisition. The unit economics in this vertical are better than most founders realize.
## 5. Compounded peptides create a power-user segment.
Beyond branded GLP-1s (Ozempic, Wegovy), theres a massive compounded peptide market. These users need reconstitution calculators, dosing protocols, and inventory tracking.
This is a power-user segment willing to pay $5-15/month for premium features. PeptideCalc already charges $4.99 one-time and has 4.9 stars. A subscription model with creator-driven acquisition could scale this significantly.
The opportunity for founders.
If I were building a GLP-1 app from scratch in 2026, heres the playbook:
· Start with the compounded peptide niche (highest willingness to pay, underserved)
· Build the best reconstitution calculator + tracking combo
· Launch with 5-10 creators on TikTok posting GLP-1 journey content
· Use the before-after format as the core creative
· Target r/Mounjaro, r/tirzepatidecompound with organic posts
· Price at $4.99/month or $29.99/year (the market supports it)
· Expand to branded GLP-1 users once the creator engine is running
Cal AI went from a tracking app to $50M ARR by adding a creator engine. The GLP-1 category is the same product type, same user behavior, same before-after content format, with a market thats 10x bigger and 5 years behind on marketing sophistication.
## The opportunity for growth agencies.
This is also a massive opportunity for agencies that specialize in creator-driven app growth (full disclosure: thats us).
The GLP-1 vertical has:
· High LTV users (medical adherence = daily opens)
· Natural content formats (before-after, day-in-my-life, tutorial)
· Massive organic search volume ("ozempic tracker", "glp-1 app", "peptide calculator")
· Almost zero competition for creator attention in the niche
· Clients with real revenue already ($300K/month for the leader)
The first agency to build a GLP-1 creator network will have a significant head start (we already started ; ) ). The creators who do this content well dont exist yet at scale. Building that network now is the moat.
The bigger picture.
Every major health trend creates an app category that follows a predictable arc:
· Phase 1: The drug/treatment goes mainstream (GLP-1s: 2023-2025)
· Phase 2: Tracking apps appear, grow on organic/Reddit (where we are now)
· Phase 3: One app adds a creator engine and separates from the pack
· Phase 4: Category consolidation, acquisitions, $50M+ outcomes
We saw this exact arc with calorie tracking (Cal AI), meditation (Calm/Headspace), and cycle tracking (Flo). Each time, the app that won Phase 3 owned the category for years.
GLP-1 apps are at the end of Phase 2. Phase 3 hasn't started yet. The window is open.
30 million users. $50B+ drug market. Less than 1% app penetration. Zero creator marketing.
> The biggest gold rush in mobile health is happening right now. Almost nobody in the growth world is paying attention.
## 相关链接
- [Lucas Patiri](https://x.com/lucaspatiri_)
- [@lucaspatiri_](https://x.com/lucaspatiri_)
- [15K](https://x.com/lucaspatiri_/status/2046577435269898403/analytics)
- [Upgrade to Premium](https://x.com/i/premium_sign_up)
- [9:10 PM · Apr 21, 2026](https://x.com/lucaspatiri_/status/2046577435269898403)
- [15.2K Views](https://x.com/lucaspatiri_/status/2046577435269898403/analytics)
- [View quotes](https://x.com/lucaspatiri_/status/2046577435269898403/quotes)
---
*导出时间: 2026/4/22 12:03:02*
---
## 中文翻译
# 有一个月入30万美元的应用，你从没听说过。这是一场无人谈论的GLP-1应用淘金热。
**作者**: Lucas Patiri
**日期**: 2026-04-21T13:10:58.000Z
**来源**: [https://x.com/lucaspatiri_/status/2046577435269898403](https://x.com/lucaspatiri_/status/2046577435269898403)
---
全球有3000万人在服用减肥药，但几乎没有人使用专门的应用。这个品类目前（暂时）还没有任何创作者营销。这是移动领域最大的未开发垂直市场。
目前全球有3000万人正在服用GLP-1药物：Ozempic、Wegovy、Mounjaro、Zepbound。每八个美国成年人中就有一个正在服用其中一种。
GLP-1药物市场规模超过500亿美元，并以每年20%以上的速度增长。到2030年，它将成为历史上最大的药品品类。
然而，应用增长领域几乎没有人关注建立在其之上的软件层。
有一款叫Shotsy的GLP-1追踪应用，月收入达30万美元，每月下载量4万次，总用户接近100万，在美国App Store健康与健身类排名第152位。
你很可能从没听说过它。
这件事为什么重要：GLP-1应用品类就像2018年的健身应用市场——处于早期、增长迅速、市场规模巨大，而且这些应用在获取和留存用户方面几乎毫无成熟打法。
这个领域没有人做创作者营销，没有人在大规模做UGC（用户生成内容）。整个品类完全靠Reddit论坛和医生推荐带来的自然口碑增长。
如果你是一个正在寻找下一个垂直领域的应用创始人，或者是一个正在寻找蓝海市场的增长操盘手，那就是这里。
先看数据。
先从药物市场说起，因为应用机会是它的直接函数。
· 全球目前有3000万人服用GLP-1药物
· 每8个美国成年人中就有1个正在服用GLP-1药物
· 全球27%的成年人符合GLP-1治疗条件
· 2026年药物市场规模达500-800亿美元，复合年增长率超过20%
· 预计到2035年，将有5500万美国人服用GLP-1药物
再看应用端：
· Shotsy：月收入30万美元，月下载量4万次，总用户约100万
· MeAgain：用户超过25万，评分4.81星，订阅模式
· Pep：下载量超过1.1万次，快速增长
· PeptideCalc：一次性购买4.99美元，评分4.9星，小众但用户忠诚
· 整个品类年收入：所有应用合计估计为500-600万美元
最后一个数字最值得注意。为3000万用户的市场服务却只有500-600万美元年收入，意味着渗透率不足1%。这个领域的头部应用在一个超过500亿美元的市场中年收入仅为360万美元。
作为对比：Cal AI在一个规模小得多的卡路里追踪市场中做到了5000万美元ARR。GLP-1应用的机会更大，竞争也更少。
为什么没有人在推广这些应用。
我研究了所有主流GLP-1应用，并检查了它们的增长渠道。以下是我的发现：
· TikTok、Reels或Shorts上没有任何活跃的UGC或创作者营销活动
· 没有可见的网红合作关系
· Meta或TikTok上没有付费社交广告库
· 增长几乎完全靠自然流量：Reddit（r/Mounjaro、r/tirzepatidecompound）、医生推荐和App Store搜索
这正是五年前健身应用行业的状态。在Cal AI零广告投入却获得2.5亿次浏览之前，在Hevy和Lose It这类应用建立创作者网络之前，在UGC成为健康类应用默认增长引擎之前。
GLP-1应用领域还没有迎来它的UGC时刻。一旦到来，先发者将占据主导地位。
为什么创作者内容最适合这个垂直领域。
GLP-1内容已经在社交媒体上爆发式增长。关于Ozempic、Mounjaro、减肥历程、副作用、GLP-1饮食规划的帖子数以百万计。受众存在，内容需求存在，但没有人把它引导到某个应用上。
以下是创作者营销在这个领域特别有效的原因：
## 1. 前后对比的形态是产品自带的。
减肥是现存最具视觉冲击力的转变类目。每个GLP-1用户都有前后对比的故事。创作者展示自己3个月或6个月的转变，同时提到帮助他们追踪的应用，这是最自然的广告形式。
Cal AI深谙此道。他们表现最好的内容永远是前后对比。GLP-1应用还没想明白这一点。
## 2. 受众迫切需要指导和社群。
开始使用GLP-1让人困惑又害怕。剂量安排、配液（针对配制型药物）、注射部位、副作用、蛋白质摄入要求、补水……人们不堪重负。
当创作者说“这是我用来追踪一切的应用”时，会立刻提供价值。这不是推销，而是一条生命线。这种转化意向比几乎所有其他垂直领域都强。
## 3. 病耻感带来亲密感。
减肥药仍然存在污名化。人们不总是公开谈论它。但他们确实会与真实分享经历的人创作的创作者内容互动。
公开自己GLP-1历程的创作者与受众建立了异常深厚的信任。这种信任会直接转移到他们推荐的应用上。在有病耻感的健康垂直领域，转化率通常比一般健康内容高2-3倍。
## 4. 医疗内容的留存率更高。
GLP-1追踪是与医疗日常挂钩的每日习惯。药物追踪应用的留存曲线明显比一般健身应用平缓。
更高的留存率=更高的LTV=更多的获客预算。这个垂直领域的单位经济模型比大多数创始人意识到的要好。
## 5. 配制型肽类药物创造了一个高粘性用户群体。
除了品牌GLP-1药物（Ozempic、Wegovy）之外，还有一个庞大的配制肽类药物市场。这些用户需要配液计算器、给药方案和库存追踪。
这是一个愿意为高级功能支付每月 5-15 美元的重度用户群体。PeptideCalc 已经收取 4.99 美元的一次性费用，并获得 4.9 星评分。采用订阅模式并借助创作者驱动获客，可以显著扩大规模。
创始人的机会。
如果我要在 2026 年从零开始打造一款 GLP-1 应用，打法如下：
· 从复合肽细分市场入手（付费意愿最高，服务不足）
· 打造最好的重组计算器 + 追踪组合
· 与 5-10 位 TikTok 创作者合作发布，分享 GLP-1 使用历程内容
· 以前后对比形式作为核心创意
· 通过自然发帖针对 r/Mounjaro、r/tirzepatidecompound
· 定价每月 4.99 美元或每年 29.99 美元（市场可以接受）
· 待创作者引擎运转后，再扩展到品牌 GLP-1 用户
Cal AI 从一款追踪应用通过加入创作者引擎做到了 5000 万美元 ARR。GLP-1 这个品类是同样的产品类型、同样的用户行为、同样的前后对比内容形式，而市场规模大 10 倍，营销成熟度落后 5 年。
## 增长代理机构的机会。
对于专注创作者驱动应用增长的代理机构来说，这也是一个巨大的机会（坦诚说明：我们就是其中之一）。
GLP-1 垂直领域具备：
· 高 LTV 用户（医疗依从性 = 每日打开）
· 天然的内容形式（前后对比、我的一天、教程）
· 海量的自然搜索流量（"ozempic tracker"、"glp-1 app"、"peptide calculator"）
· 创作者注意力领域内几乎零竞争
· 已有真实收入的客户（头部产品月收入 30 万美元）
第一家建立 GLP-1 创作者网络的代理机构将拥有显著的先发优势（我们已经开始行动了 ; ) ）。擅长这类内容的创作者目前尚未规模化存在。现在建立这个网络就是护城河。
更大的图景。
每一个重大健康趋势都会催生一个应用品类，并遵循可预测的发展轨迹：
· 阶段 1：药物/疗法走向主流（GLP-1：2023-2025）
· 阶段 2：追踪应用出现，依靠自然流量/Reddit 增长（我们目前所处的阶段）
· 阶段 3：某款应用加入创作者引擎，从同质化竞争中脱颖而出
· 阶段 4：品类整合、收购，出现 5000 万美元以上的成果
我们在卡路里追踪（Cal AI）、冥想（Calm/Headspace）和经期追踪（Flo）上看到了完全相同的轨迹。每一次，赢得阶段 3 的应用都掌控了该品类多年。
GLP-1 应用正处于阶段 2 的末期。阶段 3 尚未开始。机会之窗是敞开的。
3000 万用户。500 亿美元以上的药物市场。不到 1% 的应用渗透率。零创作者营销。
> 移动健康领域最大的淘金热正在发生。而增长圈子里几乎没人在关注。
## 相关链接
- [Lucas Patiri](https://x.com/lucaspatiri_)
- [@lucaspatiri_](https://x.com/lucaspatiri_)
- [15K](https://x.com/lucaspatiri_/status/2046577435269898403/analytics)
- [升级至 Premium](https://x.com/i/premium_sign_up)
- [2026年4月21日 晚上9:10](https://x.com/lucaspatiri_/status/2046577435269898403)
- [15.2K 次浏览](https://x.com/lucaspatiri_/status/2046577435269898403/analytics)
- [查看引用](https://x.com/lucaspatiri_/status/2046577435269898403/quotes)
---
*导出时间: 2026/4/22 12:03:02*
